Illumina Joins WIN Consortium in Personalized Cancer Medicine

Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, today announced it has joined the Worldwide Innovative Networking (WIN) Consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of leading academic, industry, insurance and non-profit research organizations working to make personalized cancer care a reality for patients worldwide.

“We are very pleased to welcome Illumina to WIN,” said Dr. John Mendelsohn, Chairman of the WIN Consortium and the Director of the Khalifa Institute for Personalized Cancer Therapy at MD Anderson Cancer Center. “Their expertise will be invaluable as we work to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials, the most promising advances in genomic-based cancer research.”

“The WIN Consortium is uniquely bringing together renowned institutions and cancer researchers from around the world. By working together, we will be able to generate the type of clinical utility data needed to define the value of next-generation genomic testing for oncology, as well as newer methods such as liquid biopsy,” said John Leite, Vice President of Illumina’s Oncology business. “We look forward to collaborating, with the ultimate goal of making personalized therapy a reality for cancer patients.”

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

About the WIN Consortium

Founded in 2010, WIN is an initiative from the Institut Gustave Roussy (France) and University of Texas MD Anderson Cancer Center (USA). WIN is unique structurally in that it brings together organizations from academia, business and not-for-profits to focus on translating the latest advances in personalized cancer medicine into the standard of care. WIN is built on the recognition that all stakeholders in personalized cancer therapy must collaborate and share information, in order to effectively bring the latest innovations in personalized cancer care to the patient. WIN is a non-profit organization formed by 40 renowned members: Academic cancer centres (25 centers in 17 countries), companies (Blue Cross Blue Shield, Agilent Technologies, GE Healthcare, Oracle Health Services, Foundation Medicine, Takeda, AstraZeneca and Pfizer), and non-profit organizations such as EORTC, CRUK and Fondation ARC. WIN organizes an annual symposium in Paris dedicated to personalized medicine. For further information, please visit www.winconsortium.org and www.winsymposium.org.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150923005359/en/

Illumina, Inc.Investors:Rebecca Chambers, [e-mail]:Jennifer Temple, [e-mail] ConsortiumVladimir Lazar, 33 66 109 15 [e-mail]